Rare Variants in Complement Genes May Not Be That Rare After All

Sjoerd A.M.E.G. Timmermans; Daan P.C. van Doorn; Pieter van Paassen

doi:10.1016/j.ekir.2023.08.020

Rare Variants in Complement Genes May Not Be That Rare After All

Sjoerd A.M.E.G. Timmermans^*, Daan P.C. van Doorn, Pieter van Paassen

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	1911-1913
Number of pages	3
Journal	Kidney International Reports
Volume	8
Issue number	10
Early online date	23 Aug 2023
DOIs	https://doi.org/10.1016/j.ekir.2023.08.020
Publication status	Published - Oct 2023

Access to Document

10.1016/j.ekir.2023.08.020Licence: CC BY-NC-ND

Cite this

@article{424c879035f6401ba375231c3ad57b5f,

title = "Rare Variants in Complement Genes May Not Be That Rare After All",

author = "Timmermans, {Sjoerd A.M.E.G.} and {van Doorn}, {Daan P.C.} and {van Paassen}, Pieter",

note = "Funding Information: SAMEGT received funding from the Dutch Kidney Foundation (i.e., Nierstichting; 23OK1056). Funding Information: SAMEGT participated in TMA expert meetings and received travel/speaker fees from Alexion Pharmaceuticals Inc. (AstraZeneca). PvP received unrestricted research grants from Alexion Pharmaceuticals Inc. (AstraZeneca) and ChemoCentryx (Amgen). DPCvD declares no competing interests.",

year = "2023",

month = oct,

doi = "10.1016/j.ekir.2023.08.020",

language = "English",

volume = "8",

pages = "1911--1913",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Rare Variants in Complement Genes May Not Be That Rare After All

AU - Timmermans, Sjoerd A.M.E.G.

AU - van Doorn, Daan P.C.

AU - van Paassen, Pieter

N1 - Funding Information: SAMEGT received funding from the Dutch Kidney Foundation (i.e., Nierstichting; 23OK1056). Funding Information: SAMEGT participated in TMA expert meetings and received travel/speaker fees from Alexion Pharmaceuticals Inc. (AstraZeneca). PvP received unrestricted research grants from Alexion Pharmaceuticals Inc. (AstraZeneca) and ChemoCentryx (Amgen). DPCvD declares no competing interests.

PY - 2023/10

Y1 - 2023/10

U2 - 10.1016/j.ekir.2023.08.020

DO - 10.1016/j.ekir.2023.08.020

M3 - Editorial

SN - 2468-0249

VL - 8

SP - 1911

EP - 1913

JO - Kidney International Reports

JF - Kidney International Reports

IS - 10

ER -